View source for Eberhart 2009 Leukemia

{{Publication
|title=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 23:2167-70.
|info=[http://www.ncbi.nlm.nih.gov/pubmed/19657369 PMID: 19657369]; [http://www.nature.com/leu/journal/v23/n11/full/leu2009154a.html Open Access]
|authors=Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ
|year=2009
|journal=Leukemia
|abstract=Glucocorticoids (GCs) are an essential component of most chemotherapy protocols for lymphoid malignancies, particularly childhood acute lymphoblastic leukemia (ALL).1, 2 Nevertheless, adverse side effects of GCs call for improved therapy protocols.

GCs decrease the activity of glycolytic enzymes3 and upregulate the expression of the glycolytic regulator, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase ''in vitro'' and ''in vivo''.4 This led us to investigate whether co-administration of 2-deoxy-glucose (2-DG), an inhibitor of glycolysis, systemic application of which up to a blood concentration of approximately 3 mM had caused a transient hyperglycemia only,5 might potentiate the apoptotic effect of GC.
}}
{{Labeling
|area=Respiration
|organism=Human
|tissues=Blood cells
|model cell lines=Lymphocyte
|preparations=Intact cells
|diseases=Cancer
|couplingstates=LEAK, ROUTINE, ETS
|substratestates=ROX
|instruments=Oxygraph-2k
}}